A randomised trial examining the effectiveness of sympathetic nervous inhibition in alleviating the metabolic side effects of antipsychotic medications in patients with schizophrenia

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1022794

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Despite improved diagnosis and increased use of antipsychotic medications the mortality risk in patients with schizophrenia remains 2-3 times that of the general population, largely due to cardiovascular disease development. In this project we will test the effectiveness of sympathetic nervous inhibition with moxonidine (as add on therapy) in alleviating the metabolic side effects of antipsychotic medications in patients with schizophrenia.

Funded Activity Details

Start Date: 01-01-2012

End Date: 01-01-2015

Funding Scheme: Project Grants

Funding Amount: $477,426.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cardiology (incl. Cardiovascular Diseases)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

antipsychotic drugs | diabetes mellitus | obesity | schizophrenia | sympathetic nervous system

Related Links